CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Neoimmunetech Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Neoimmunetech Inc
2400 Research Blvd, Suite 250
Phone: (240) 801-9065p:240 801-9065 ROCKVILLE, MD  20850  United States Ticker: 950220950220
Business Summary
NeoImmuneTech is a clinical-stage biotechnology company, is focused on T cell-based therapeutics, particularly NT-I7, for treating cancer and infectious diseases. It is developing immunotherapies such as NT-I7, NEOBASE, NT2020, NT3020, NT4010, and NT5010. It conducts clinical trials of NT-I7 with various therapeutics, including immune checkpoint inhibitors, and continues basic research and animal studies. NT-I7 is a T cell amplifier with the potential to enhance T cell numbers and immunological functions. NEOBASE is a heterodimer Fragment crystallizable region (FC) platform designed to enhance structural stability and immune response-promoting capabilities. NT2020 is a T cell activator based on PROTAC technology designed to eliminate specific target proteins. NT3020 is an antibody-based biologic. NT4010 is an advanced Chimeric Antigen Receptor T-cell (CAR-T) technology, and NT5010 is an effector T regulatory cells (eTreg) depletory technology targeting effector Treg cells in tumors.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Business Names
Business Name
950220
NEOIMMUNETECH INC

General Information
Outstanding Shares: 19,773,493 (As of 9/30/2024)
Shareholders: 40,090
Stock Exchange: KDQ
Fax Number: (240) 595-6132
Email Address: info@neoimmunetech.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 29, 2025